{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:33:25Z","timestamp":1762673605322},"reference-count":47,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3137,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2006.01237.x","type":"journal-article","created":{"date-parts":[[2007,2,2]],"date-time":"2007-02-02T18:22:23Z","timestamp":1170440543000},"page":"293-302","source":"Crossref","is-referenced-by-count":52,"title":["Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature"],"prefix":"10.1155","volume":"61","author":[{"given":"O.","family":"Lidove","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Barbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bekri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-F","family":"Alexandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Peigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Jaussaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Papo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2007,1,29]]},"reference":[{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB1|cit1","first-page":"3733","volume-title":"The Metabolic and Molecular Basis of Inherited Disease","author":"Desnick","year":"2001"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","article-title":"Cerebrovascular complications of Fabry's disease","volume":"40","author":"Mitsias","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(01)05816-0","article-title":"Enzyme-replacement therapy for Anderson-Fabry disease","volume":"358","author":"Pastores","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB11|cit11","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0895-4356(94)00098-B","article-title":"Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias","volume":"48","author":"Gregoire","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","article-title":"Bias in location and selection of studies","volume":"316","author":"Egger","year":"1998","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0895-4356(92)90072-U","article-title":"Bias in meta-analytic research","volume":"45","author":"Felson","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/B:BOLI.0000028794.04349.91","article-title":"CNS involvement in Fabry disease: clinical and imaging studies before and after 12\u2003months of enzyme replacement therapy","volume":"27","author":"Jardim","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study","volume":"26","author":"Baehner","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin Genet"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bmj.331.7521.895","article-title":"Disappointing biotech","volume":"331","author":"Joppi","year":"2005","journal-title":"Br Med J"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1212\/WNL.50.6.1746","article-title":"Quantitative analysis of cerebral vasculopathy in patients with Fabry disease","volume":"50","author":"Crutchfield","year":"1998","journal-title":"Neurology"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2377-2-4","article-title":"Abnormal cerebrovascular reactivity in Fabry disease is reversed following enzyme replacement therapy","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Neurol"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med Genet"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/B:BOLI.0000009948.86528.72","article-title":"Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy","volume":"26","author":"Hajioff","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB34|cit34","first-page":"246","article-title":"Gastrointestinal structure and function in Fabry's disease","volume":"76","author":"Sheth","year":"1981","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","article-title":"Quality of life of patients with Fabry disease","volume":"11","author":"Gold","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1015009210639","article-title":"Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention","volume":"11","author":"Miners","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/B:BOLI.0000037342.59612.69","article-title":"Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease","volume":"27","author":"Dehout","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1523-1755.2005.00294.x","article-title":"Anemia is a new complication in Fabry disease: data from the Fabry outcome survey","volume":"67","author":"Kleinert","year":"2005","journal-title":"Kidney Int"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1517\/13543784.11.10.1467","article-title":"Fabry disease: recent advances in enzyme replacement therapy","volume":"11","author":"Germain","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB42|cit42","volume-title":"European Public Assessment Report for Replagal","author":"European Agency for the Evaluation of Medicinal Products","year":"2001"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB43|cit43","volume-title":"European Public Assessment Report for Fabrazyme","author":"European Agency for the Evaluation of Medicinal Products","year":"2001"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB46|cit46","first-page":"287","article-title":"Recurrence of Fabry's disease in a renal allograft 14\u2003years after transplantation","volume":"10","author":"Gantenbein","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1742-1241.2006.01237.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/187152506778520718","article-title":"The role of globotriaosylceramide in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature","volume":"4","author":"Bekri","year":"2006","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2006.01237.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2006.01237.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:06:55Z","timestamp":1643350015000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2006.01237.x"}},"subtitle":["Enzyme replacement therapy in FD"],"short-title":[],"issued":{"date-parts":[[2007,1,29]]},"references-count":47,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01237.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1,29]]}}}